Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Overactive Bladder - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Overactive Bladder - Pipeline Review, H1 2016', provides an overview of the Overactive Bladder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Overactive Bladder - The report reviews pipeline therapeutics for Overactive Bladder by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Overactive Bladder therapeutics and enlists all their major and minor projects - The report assesses Overactive Bladder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Overactive Bladder Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Overactive Bladder - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Overactive Bladder Overview 10 Therapeutics Development 11 Pipeline Products for Overactive Bladder - Overview 11 Pipeline Products for Overactive Bladder - Comparative Analysis 12 Overactive Bladder - Therapeutics under Development by Companies 13 Overactive Bladder - Therapeutics under Investigation by Universities/Institutes 15 Overactive Bladder - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Overactive Bladder - Products under Development by Companies 19 Overactive Bladder - Products under Investigation by Universities/Institutes 21 Overactive Bladder - Companies Involved in Therapeutics Development 22 Addex Therapeutics Ltd 22 Asahi Kasei Pharma Corp. 23 Astellas Pharma Inc. 24 Dompe Farmaceutici S.p.A. 25 FemmePharma Global Healthcare, Inc. 26 Hydra Biosciences, Inc. 27 Ion Channel Innovations, LLC 28 Jeil Pharmaceutical Co., Ltd. 29 Juniper Pharmaceuticals, Inc. 30 Lipella Pharmaceuticals, Inc. 31 Merck & Co., Inc. 32 Mezzion Pharma Co. Ltd. 33 MI.TO. Technology S.r.L. 34 Recordati S.p.A. 35 Sanofi 36 Sihuan Pharmaceutical Holdings Group Ltd. 37 Taris Biomedical LLC 38 TheraVida, Inc. 39 Toray Industries, Inc. 40 UroGen Pharmaceuticals, Ltd. 41 Overactive Bladder - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 (mirabegron + solifenacin succinate) - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ADX-71441 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 DA-8010 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 DFL-23448 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 fadanafil - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 HC-067047 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 mirabegron ER - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 onabotulinumtoxin A - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 onabotulinumtoxinA SR - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 oxybutynin chloride - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 oxybutynin chloride - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 oxybutynin hydrochloride - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pVAX-hSlo - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 REC-0438 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SAR-244181 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules to Block TRPV1 for Overactive Bladder - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 solabegron hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 solifenacin succinate - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 solifenacin succinate - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 tacrolimus - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TAR-302 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 THVD-201 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 THVD-202 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 udenafil - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 vibegron - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Overactive Bladder - Recent Pipeline Updates 89 Overactive Bladder - Dormant Projects 100 Overactive Bladder - Discontinued Products 105 Overactive Bladder - Product Development Milestones 107 Featured News & Press Releases 107 Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women 107 Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product 107 Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder 108 May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 109 May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 110 Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial 110 Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 111 Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder 111 Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 112 May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 112 Appendix 113 Methodology 113 Coverage 113 Secondary Research 113 Primary Research 113 Expert Panel Validation 113 Contact Us 113 Disclaimer 114
List of Tables
Number of Products under Development for Overactive Bladder, H1 2016 11 Number of Products under Development for Overactive Bladder - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H1 2016 22 Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H1 2016 23 Overactive Bladder - Pipeline by Astellas Pharma Inc., H1 2016 24 Overactive Bladder - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 25 Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H1 2016 26 Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H1 2016 27 Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H1 2016 28 Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 29 Overactive Bladder - Pipeline by Juniper Pharmaceuticals, Inc., H1 2016 30 Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H1 2016 31 Overactive Bladder - Pipeline by Merck & Co., Inc., H1 2016 32 Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 33 Overactive Bladder - Pipeline by MI.TO. Technology S.r.L., H1 2016 34 Overactive Bladder - Pipeline by Recordati S.p.A., H1 2016 35 Overactive Bladder - Pipeline by Sanofi, H1 2016 36 Overactive Bladder - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 37 Overactive Bladder - Pipeline by Taris Biomedical LLC, H1 2016 38 Overactive Bladder - Pipeline by TheraVida, Inc., H1 2016 39 Overactive Bladder - Pipeline by Toray Industries, Inc., H1 2016 40 Overactive Bladder - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 41 Assessment by Monotherapy Products, H1 2016 42 Assessment by Combination Products, H1 2016 43 Number of Products by Stage and Target, H1 2016 45 Number of Products by Stage and Mechanism of Action, H1 2016 47 Number of Products by Stage and Route of Administration, H1 2016 49 Number of Products by Stage and Molecule Type, H1 2016 51 Overactive Bladder Therapeutics - Recent Pipeline Updates, H1 2016 89 Overactive Bladder - Dormant Projects, H1 2016 100 Overactive Bladder - Dormant Projects (Contd..1), H1 2016 101 Overactive Bladder - Dormant Projects (Contd..2), H1 2016 102 Overactive Bladder - Dormant Projects (Contd..3), H1 2016 103 Overactive Bladder - Dormant Projects (Contd..4), H1 2016 104 Overactive Bladder - Discontinued Products, H1 2016 105 Overactive Bladder - Discontinued Products (Contd..1), H1 2016 106
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
